Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids

Joseph V. Pergolizzi, Sumedha A. Labhsetwar, R. Amy Puenpatom, Rami Ben-Joseph, Robert Ohsfeldt, Kent H. Summers

Research output: Contribution to journalArticle

Abstract

Patients with osteoarthritis (OA) taking at least one CYP450-metabolized opioid concurrently with another CYP450-metabolized medication experience a drug-drug exposure (DDE), which puts them at risk of a pharmacokinetic drug-drug interaction (PK DDI). This study compared patients with and without such an incident DDE to determine healthcare utilization and associated payments. Using a retrospective database analysis, the impact of DDEs was evaluated in terms of associated clinical events, healthcare services utilization (office visits, outpatient visits, ED visits, hospitalization), and payments in patient populations based on age (those under age 65 and those 65years of age and older), during the 6months after exposure. DDE patients had significantly more inpatient hospitalizations than no-DDE patients. Mean total payments at 6months were significantly higher for both younger and older patients with DDE compared to similar patients without DDE ($9,469, SD=$12,192 vs. $8,382, SD=$14,078, respectively, for younger patients, resulting in a difference of $1,087, P

Original languageEnglish (US)
Pages (from-to)33-44
Number of pages12
JournalPain Practice
Volume12
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Drug Interactions
Osteoarthritis
Opioid Analgesics
Economics
Pharmaceutical Preparations
Hospitalization
Delivery of Health Care
Dichlorodiphenyl Dichloroethylene
Office Visits
Inpatients
Outpatients
Pharmacokinetics
Databases

Keywords

  • Analgesics
  • Narcotics
  • Opioid Analgesics
  • Opioid Arthritis
  • Opioids
  • Pharmacologic Actions
  • Therapeutics

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Pergolizzi, J. V., Labhsetwar, S. A., Puenpatom, R. A., Ben-Joseph, R., Ohsfeldt, R., & Summers, K. H. (2012). Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pain Practice, 12(1), 33-44. https://doi.org/10.1111/j.1533-2500.2011.00498.x

Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. / Pergolizzi, Joseph V.; Labhsetwar, Sumedha A.; Puenpatom, R. Amy; Ben-Joseph, Rami; Ohsfeldt, Robert; Summers, Kent H.

In: Pain Practice, Vol. 12, No. 1, 01.2012, p. 33-44.

Research output: Contribution to journalArticle

Pergolizzi, JV, Labhsetwar, SA, Puenpatom, RA, Ben-Joseph, R, Ohsfeldt, R & Summers, KH 2012, 'Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids', Pain Practice, vol. 12, no. 1, pp. 33-44. https://doi.org/10.1111/j.1533-2500.2011.00498.x
Pergolizzi JV, Labhsetwar SA, Puenpatom RA, Ben-Joseph R, Ohsfeldt R, Summers KH. Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pain Practice. 2012 Jan;12(1):33-44. https://doi.org/10.1111/j.1533-2500.2011.00498.x
Pergolizzi, Joseph V. ; Labhsetwar, Sumedha A. ; Puenpatom, R. Amy ; Ben-Joseph, Rami ; Ohsfeldt, Robert ; Summers, Kent H. / Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. In: Pain Practice. 2012 ; Vol. 12, No. 1. pp. 33-44.
@article{f5d811a66cca42c7865bcdb771e2b74c,
title = "Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids",
abstract = "Patients with osteoarthritis (OA) taking at least one CYP450-metabolized opioid concurrently with another CYP450-metabolized medication experience a drug-drug exposure (DDE), which puts them at risk of a pharmacokinetic drug-drug interaction (PK DDI). This study compared patients with and without such an incident DDE to determine healthcare utilization and associated payments. Using a retrospective database analysis, the impact of DDEs was evaluated in terms of associated clinical events, healthcare services utilization (office visits, outpatient visits, ED visits, hospitalization), and payments in patient populations based on age (those under age 65 and those 65years of age and older), during the 6months after exposure. DDE patients had significantly more inpatient hospitalizations than no-DDE patients. Mean total payments at 6months were significantly higher for both younger and older patients with DDE compared to similar patients without DDE ($9,469, SD=$12,192 vs. $8,382, SD=$14,078, respectively, for younger patients, resulting in a difference of $1,087, P",
keywords = "Analgesics, Narcotics, Opioid Analgesics, Opioid Arthritis, Opioids, Pharmacologic Actions, Therapeutics",
author = "Pergolizzi, {Joseph V.} and Labhsetwar, {Sumedha A.} and Puenpatom, {R. Amy} and Rami Ben-Joseph and Robert Ohsfeldt and Summers, {Kent H.}",
year = "2012",
month = "1",
doi = "10.1111/j.1533-2500.2011.00498.x",
language = "English (US)",
volume = "12",
pages = "33--44",
journal = "Pain Practice",
issn = "1530-7085",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids

AU - Pergolizzi, Joseph V.

AU - Labhsetwar, Sumedha A.

AU - Puenpatom, R. Amy

AU - Ben-Joseph, Rami

AU - Ohsfeldt, Robert

AU - Summers, Kent H.

PY - 2012/1

Y1 - 2012/1

N2 - Patients with osteoarthritis (OA) taking at least one CYP450-metabolized opioid concurrently with another CYP450-metabolized medication experience a drug-drug exposure (DDE), which puts them at risk of a pharmacokinetic drug-drug interaction (PK DDI). This study compared patients with and without such an incident DDE to determine healthcare utilization and associated payments. Using a retrospective database analysis, the impact of DDEs was evaluated in terms of associated clinical events, healthcare services utilization (office visits, outpatient visits, ED visits, hospitalization), and payments in patient populations based on age (those under age 65 and those 65years of age and older), during the 6months after exposure. DDE patients had significantly more inpatient hospitalizations than no-DDE patients. Mean total payments at 6months were significantly higher for both younger and older patients with DDE compared to similar patients without DDE ($9,469, SD=$12,192 vs. $8,382, SD=$14,078, respectively, for younger patients, resulting in a difference of $1,087, P

AB - Patients with osteoarthritis (OA) taking at least one CYP450-metabolized opioid concurrently with another CYP450-metabolized medication experience a drug-drug exposure (DDE), which puts them at risk of a pharmacokinetic drug-drug interaction (PK DDI). This study compared patients with and without such an incident DDE to determine healthcare utilization and associated payments. Using a retrospective database analysis, the impact of DDEs was evaluated in terms of associated clinical events, healthcare services utilization (office visits, outpatient visits, ED visits, hospitalization), and payments in patient populations based on age (those under age 65 and those 65years of age and older), during the 6months after exposure. DDE patients had significantly more inpatient hospitalizations than no-DDE patients. Mean total payments at 6months were significantly higher for both younger and older patients with DDE compared to similar patients without DDE ($9,469, SD=$12,192 vs. $8,382, SD=$14,078, respectively, for younger patients, resulting in a difference of $1,087, P

KW - Analgesics

KW - Narcotics

KW - Opioid Analgesics

KW - Opioid Arthritis

KW - Opioids

KW - Pharmacologic Actions

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84855718947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855718947&partnerID=8YFLogxK

U2 - 10.1111/j.1533-2500.2011.00498.x

DO - 10.1111/j.1533-2500.2011.00498.x

M3 - Article

C2 - 21951824

AN - SCOPUS:84855718947

VL - 12

SP - 33

EP - 44

JO - Pain Practice

JF - Pain Practice

SN - 1530-7085

IS - 1

ER -